The centralized procurement of Chinese patent medicines is continuously advancing, and it is urgent for the enterprises to control costs and ensure the quality of Chinese patent medicines.

At present, the "big knife" of centralized procurement has extended from chemical medicines and high-value consumables to the field of Chinese patent medicines
.
Although the country has not fully promoted the inclusion of proprietary Chinese medicines in centralized procurement, local governments are actively exploring.
For example, in the recent past, there have been many large-scale proprietary Chinese medicine alliances in the industry
.
In April, Guangdong took the lead in the centralized procurement of medicines in the 16-province alliance involving dozens of proprietary Chinese medicines
.
On September 14, the Guangdong Provincial Drug Trading Center issued the "Guangdong Union Qingkailing and other 58 drug groups with volume procurement documents (draft for comments)", intending to purchase 58 commonly used Chinese patent medicines with volume.
The procurement alliance involves There are 7 provincial administrative regions including Guangdong, Shanxi, Henan, Hainan, Ningxia, Qinghai, and Xinjiang
.
Centralized procurement of Chinese patent medicines is continuously advancing (picture source: Pharmaceutical Network) Subsequently, the Hubei Province Pharmaceutical Price and Bidding Procurement Management Service Network also issued the "Announcement of Centralized Procurement of Proprietary Chinese Medicines by the Interprovincial Alliance (No.
1)", which clearly stated that Hubei The province will work with 18 provinces including Hebei, Shanxi, and Inner Mongolia to carry out centralized procurement of Chinese patent medicines
.
With the continuous advancement of centralized procurement of proprietary Chinese medicines, the industry generally believes that relevant pharmaceutical companies will face the test of price cuts
.
In fact, in the past, the centralized procurement of medicines often led to a large drop in product prices
.
It is worth noting that in the case of drugs facing price cuts, the analysis believes that Chinese patent medicine companies will also face risks such as large price fluctuations of raw medicinal materials and difficulty in cost control
.
It is understood that since the beginning of this year, a large number of traditional Chinese medicines have seen price increases in the Chinese herbal medicine market in various places
.
For example, in the lotus pond Chinese medicinal material market in Chengdu, Sichuan, the price of nearly 80% of Chinese medicine has risen significantly recently, and the price increase of individual varieties has even reached 200% to 300%
.
"Lily may have risen by more than ten yuan per kilogram, and ginseng has risen by 100 yuan per kilogram
.
It used to sell for more than 300 yuan, and now it sells for more than 400 yuan.
The price
has started to increase when new products are produced .
" Some merchants said
.
Under the dual pressure of price reduction in centralized procurement and price increase of raw materials, the industry believes that how to balance price reduction and quality control has become an urgent problem to be solved in the development of Chinese patent medicine enterprises.

.
So, in the face of the continuous advancement of centralized procurement, how should Chinese patent medicine companies control costs and ensure quality? In this regard, the industry proposes that pharmaceutical companies must first be prepared to actively meet regulatory requirements, such as building a planting base for Chinese medicinal materials that meets GAP specifications to ensure stable product quality, redundant production capacity, and a strong market share.
and so on
.
In addition, innovations in existing rules are more beneficial to companies that have a large market share and a relatively stable market
.
Therefore, companies that want to achieve better development must conduct a comprehensive analysis of cost, price and volume
.
Companies should consider various uncertain factors, improve supply chain management, and reasonably estimate the quotation space from a cost perspective.
At the same time, they should increase R&D investment, improve quality standards, and accelerate the construction of a TCM standardization system to form group standards, local standards, and industry standards.
Standards, national standards, international standards, and a multi-level, multi-dimensional, and whole-process quality control system covering medicinal materials, intermediates, and finished products
.
It is worth noting that many of these links are actually inseparable from the help of pharmaceutical equipment
.
For a long time, pharmaceutical equipment has been closely related to the research and development, production, and testing of Chinese medicines.
The quality of its quality and the advanced technology often have a direct impact on the quality of Chinese patent medicines
.
Based on this, the industry believes that it is necessary to attach importance to and strengthen the modernization of related pharmaceutical equipment, and to design and develop equipment that can not only guarantee the quality of medicines, but also save energy and increase efficiency according to the needs of Chinese patent medicines
.
It is reported that many pharmaceutical equipment companies have begun to upgrade their products
.
If there is a pulverizer manufacturer, they have developed a low-temperature ultrafine pulverizer, which is a process application equipment with cell-level fine pulverization technology as the core.
It has the advantages of high pulverization efficiency and strong pulverization ability
.
It can be adapted to materials with fibrous, high toughness, high hardness and water content less than 6%, low energy consumption, low temperature, no residue after crushing, which can avoid material loss and increase production efficiency.

.
In addition, some companies have created a drug crushing pulse dust removal unit.
According to reports, the unit is composed of a crushing host, a powder collecting classifier, a cyclone separator, a dust removal filter, and an electric control cabinet for Yinfeng.
, Has the advantages of good performance, high efficiency, low noise, low energy consumption, environmental protection and energy saving, and meets GMP certification standards
.
In general, with the continuous advancement of centralized procurement of Chinese patent medicines, enterprises will have higher and higher requirements for cost control and quality
.
Affected by this, related pharmaceutical equipment companies will also usher in more opportunities
.
However, it should be noted that at the same time, related pharmaceutical equipment companies will increasingly need the support of advanced technology and equipment
.
Therefore, if pharmaceutical equipment companies want to gain more development opportunities in the future, they still need to rely on innovation to continue to move forward
.